Farallon Capital Management is waging a proxy battle with Exelixis over R&D spending. The hedge fund issued a letter to the company’s board of directors on Wednesday.
Tag Archive for: Mereo BioPharma
Following recent meetings with the FDA and European Medicines Agency (EMA), Mereo Biopharma is designing a Phase III study of alvelestat to treat alpha-1-antitrypsin deficiency-associated lung disease.
Mereo BioPharma will cut 40% of its headcount and significantly reduce expenses to support the advancements of its lead programs through the clinic, the company announced Tuesday.
Pharmaceutical powerhouse AstraZeneca appears to have taken an interest in the company’s London-based partner Mereo BioPharma and may be considering a buyout, according to circulating speculations first reported by The Times UK.
